Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/30/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its US operating subsidiary, Theravance Biopharma US, Inc. , that it will release financial results for the period ended September 30,

Plans for New Clinical Studies, Expanded Commercial Program and New Study Analyses Further Supporting Drug's in Vitro Potency in Resolving Difficult-to-Treat Infections


Primary and Secondary Efficacy Endpoints Met for Doses 88 mcg and Above; TD-4208 Demonstrates Clear Dose-Response Relationship and FEV1 Profile Consistent with Once-Daily Dosing

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/21/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014 : Baird 2014 Health Care

Separation Complete<br>Portfolio of Differentiated Assets Moving Forward<br>Investor & Analyst Day Planned for the Fourth Quarter

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/02/14 -- Theravance, Inc. (NASDAQ: THRX) ("Theravance") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced the completion of the separation of Theravance Biopharma, Inc.